Veradermics, a Phase 3-ready biotech developing therapies for hair loss, filed on Friday with the SEC to raise up to $100 million in an initial public offering.
Veradermics Therapeutics is a dermatologist-founded, late clinical-stage biopharmaceutical company focused on developing an oral, non-hormonal extended-release formulation of minoxidil (VDPHL01) to address male and female pattern hair loss affecting approximately 50 million men and 30 million women in the United States. The company has fully enrolled a 519-patient Phase 2-3 trial in male patients and has initiated two additional registration-directed, randomized, double-blind, placebo-controlled Phase 3 trials targeting 498 male patients and 552 female patients to support a 505(b)(2) NDA.
The New Haven, CT-based company was founded in 2019 and plans to list on the NYSE under the symbol MANE. Veradermics filed confidentially on October 27, 2025. Jefferies, Leerink Partners, Citi, and Cantor Fitzgerald are the joint bookrunners on the deal. No pricing terms were disclosed.
